FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to modified hemagglutinins (HA) of the influenza virus, and can be used in medicine for the preparation of a medicament for the treatment or prevention of infection caused by the H5 influenza virus. Modified H5 HA polypeptide that differs from the reference H5 HA polypeptide by at least substitutions of Q226L and / or G228S and includes a deletion at position 130, and preferably does not contain glycosylation at position 158, is obtained, wherein the numbering of amino acid positions is based on the canonical numbering system H3.
EFFECT: invention makes it possible to obtain a modified HA polypeptide that competes for the glycan-HA polypeptide interaction between the glycan with an umbrella topology and the HA polypeptide and binds to human lung tissue, which, in turn, prevents the binding of H5 influenza virus particles to the subject's cell, and can be used in antiviral therapy.
20 cl, 28 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADAPTATION OF INFLUENZA VIRUS H5 TO HUMAN | 2014 |
|
RU2708447C2 |
| METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES | 2011 |
|
RU2604811C2 |
| HYPERGLYCOSYLATED BINDING POLYPEPTIDES | 2014 |
|
RU2708314C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY MEANS OF GLYCOENGINEERING | 2014 |
|
RU2711935C2 |
| MICA BINDING AGENTS | 2013 |
|
RU2656183C2 |
| PRODUCTION OF GLYCOPROTEINS WITH MODIFIED FUCOSYLATION | 2008 |
|
RU2479629C2 |
| HETEROMULTIMERS WITH REDUCED OR SILENCED EFFECTOR FUNCTION | 2014 |
|
RU2655439C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
| BINDING PROTEINS AND METHODS FOR USE THEREOF | 2015 |
|
RU2701434C2 |
| VERSIONS OF CHYMOSIN WITH IMPROVED PROPERTIES | 2016 |
|
RU2740317C2 |
